Displaying drugs 14201 - 14225 of 14655 in total
NLX-P101
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and …
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and …
Haloxazolam
Experimental
Illicit
3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid
Experimental
Mosapramine
Experimental
Indole Naphthyridinone
Experimental
6-Methylamino-5-Nitroisocytosine
Experimental
2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID
Experimental
Apratastat
Tmi 005 is under investigation in clinical trial NCT00095342 (Study Evaluating TMI-005 in Active Rheumatoid Arthritis).
Investigational
Ronifibrate
Experimental
Alphamethadol
Experimental
Illicit
4-Flourobenzenesulfonamide
Experimental
AL5424
Experimental
3-Amino-4-Oxybenzyl-2-Butanone
Experimental
Phenylacetaldehyde
Experimental
AL7089A
Experimental
Displaying drugs 14201 - 14225 of 14655 in total